Literature DB >> 20958176

External dacryocystorhinostomy: assessing factors that influence outcome.

Vivek B Pandya1, Scott Lee, Ross Benger, Jenny J Danks, Gina Kourt, Peter A Martin, Somsak Lertsumitkul, Peter McCluskey, Raf Ghabrial.   

Abstract

PURPOSE: To present the experience of external dacryocystorhinostomy (DCR) at a tertiary referral center and investigate factors that may affect clinical outcomes.
METHODS: The clinical records of all patients who underwent external DCR at Sydney Eye Hospital between May 2000 and August 2007 were reviewed. Data were collected in regards to patient demographics, preoperative assessment, operative details, surgical technique, postoperative management, and clinical outcomes. This information was then analyzed, with emphasis on factors that influence surgical outcomes and success.
RESULTS: A total of 338 cases were reviewed. The mean age at time of surgery was 64.82 years and the majority of patients were female (65%). Epiphora was the major preoperative symptom. Assisted local anesthesia and day stay surgery were the most common surgical settings. There was a statistically significant difference in theatre time between consultant and trainee surgeons (P < 0.00001). The mean final follow-up time was 11 months. Overall, 77.3% of patients had full resolution of symptoms and 20.8% had partial resolution. Only five patients (1.9%) had no resolution of symptoms. There was no significant difference in outcomes between consultants and trainees. Patients with anatomical nasolacrimal obstruction had significantly better outcomes compared with functional obstruction (P = 0.04). The postoperative fluorescein dye disappearance test was a good predictor of clinical success (P = 0.005). Silicone intubation for greater than 6 months was associated with better outcomes (P = 0.002).
CONCLUSIONS: The results at our tertiary center are comparable to results stated in the literature. In our series, only the amount of nasolacrimal obstruction and duration of postoperative intubation influenced surgical success.

Entities:  

Mesh:

Year:  2010        PMID: 20958176     DOI: 10.3109/01676830.2010.485715

Source DB:  PubMed          Journal:  Orbit        ISSN: 0167-6830


  8 in total

1.  [Indications and techniques for intubation of the lacrimal ducts].

Authors:  U Schaudig; P Heidari
Journal:  Ophthalmologe       Date:  2013-06       Impact factor: 1.059

2.  External dacryocystorhinostomy in consultants and fellows - a comparison of the causes of failure.

Authors:  L Sullivan; T Fearnley; A Al-Maskari; N El-Hindy; G Kalantzis; B Y Chang
Journal:  Hippokratia       Date:  2015 Jul-Sep       Impact factor: 0.471

3.  A comparison of external and endoscopic endonasal dacryocystorhinostomy for acquired nasolacrimal duct obstruction.

Authors:  R Karim; R Ghabrial; Tf Lynch; B Tang
Journal:  Clin Ophthalmol       Date:  2011-07-12

4.  External Dacryocystorhinostomy: Characteristics and Surgical Outcomes in Patients with and without Previous Dacryocystitis.

Authors:  Gilad Rabina; Shani Golan; Meira Neudorfer; Igal Leibovitch
Journal:  J Ophthalmol       Date:  2013-12-18       Impact factor: 1.909

5.  Silicone intubation indications in external dacryocystorhinostomy.

Authors:  Ibrahim Bulent Buttanri; Didem Serin
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2014

6.  Intraoperatively Observed Lacrimal Obstructive Features and Surgical Outcomes in External Dacryocystorhinostomy.

Authors:  Min Joung Lee; Sang In Khwarg; In Hyuk Kim; Jeong Hoon Choi; Youn Joo Choi; Namju Kim; Ho Kyung Choung
Journal:  Korean J Ophthalmol       Date:  2017-08-18

7.  Silicone Intubation Does not Improve the Success of Dacryocystorhinostomy in Primary Acquired Nasolacrimal Duct Obstruction.

Authors:  Farzad Pakdel
Journal:  J Ophthalmic Vis Res       Date:  2012-07

8.  Intra-Operative Mitomycin-C as Adjuvant Therapy in External and Endonasal Dacryocystorhinostomy: Systematic Review and Meta-Analysis.

Authors:  Tamata T S Sousa; Silvana A Schellini; Roberta L F S Meneghim; Antonio J M Cataneo
Journal:  Ophthalmol Ther       Date:  2020-04-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.